TG Therapeutics, Inc. stock performance trend indicates that the stock price has rallied 176.53% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 75.07% . Looking at the past 52 week period, the stock price is up at 53.63% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of TG Therapeutics, Inc. has a negative value of -47.31 compared to overall market performance.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 77.17.
TG Therapeutics, Inc. (NASDAQ:TGTX) has climbed 18.86% in the past week and advanced 191.4% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 18.58% and the outperformance has advanced to 188.08% for the last 4 weeks period.
For the current week, the company shares have a recommendation consensus of Buy. TG Therapeutics, Inc. (NASDAQ:TGTX) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.35 points or 2.52% at $13.55 with 1,845,602 shares getting traded. Post opening the session at $13.75, the shares hit an intraday low of $13.1 and an intraday high of $14 and the price was in this range throughout the day. The company has a market cap of $782 million and the number of outstanding shares has been calculated to be 57,731,109 shares. The 52-week high of TG Therapeutics, Inc. (NASDAQ:TGTX) is $15.05 and the 52-week low is $4.1.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by FBR & Co. on Mar 6, 2017 to Outperform, Raises Price Target to $ 26 from a previous price target of $24 .
Company has reported several Insider transactions to the SEC, on Jan 4, 2017, Sean A Power (CFO, Secretary and Treasurer) sold 8,816 shares at 4.55 per share price.On Jul 10, 2015, William James Kennedy (director) sold 17,000 shares at 17.08 per share price.On May 11, 2015, Biotechnologies S.a.s.u. Lfb (10% owner) purchased 114,855 shares at 6.53 per share price.
TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.